Suflex

Quick links to important sections

Suflex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suflex

Quick Facts Description
Active ingredient Mephenoxalone
Form Oral tablet
Pharmacological class Centrally acting muscle relaxant
Common use Mitigation of muscle spasticity and rigidity
Origin Synthetic compound

Identity and Classification

Suflex is a prescription-only pharmaceutical preparation whose single active ingredient is Mephenoxalone. It is formally classified as a synthetic compound, derived from the Phenoxypropazine structure, and belongs to the therapeutic class of centrally acting muscle relaxants, also known as myorelaxants. This designation signifies that the drug's primary function is to modify nerve activity within the central nervous system to help resolve conditions characterized by excessive muscle tone, a mechanism integral to its overall function. This action is utilized for the management of muscle hypertonia, providing a systemic approach for musculoskeletal relief.

The identity of Suflex is that of a monocomponent drug, typically manufactured as a film-coated tablet for oral administration, setting it apart from topical or injectable forms of myorelaxants. Its specialized positioning targets adult patients experiencing chronic muscle rigidity, offering a systemic approach to managing conditions like reflex spasms stemming from neurological disorders.


Composition and General Therapeutic Purpose

The medicine's composition relies solely on the active ingredient, Mephenoxalone, which is combined with standard solid excipients necessary for manufacturing the stable oral tablet formulation. The general purpose of Mephenoxalone is to mitigate excessive skeletal muscle hypertonia and associated spasticity, focusing on the symptomatic relief of muscular rigidity. The compound is designed to reduce the resistance of muscles to passive movement, which is a core function of the myorelaxant class.

Suflex achieves its objective by modulating nerve cell activity, particularly by enhancing inhibition at the polysynaptic reflex level within the spinal cord. This action reduces the exaggerated neural signals that instruct muscles to contract excessively, which results in a decrease in sustained, involuntary tension. The core therapeutic benefit is the relief of persistent muscular tightening and rigidity, often utilized in scenarios where muscle spasm contributes significantly to discomfort or impaired mobility.

What side effects are possible with Suflex?

The safety profile of Suflex (Mephenoxalone) is documented through regulatory review and is characterized by effects primarily related to its action as a centrally acting muscle relaxant. Safety classifications reflect categories documented in official government health authority summaries and labeling for this class of medicine.

Common and Less Common Reactions

The Nervous System is the most frequently affected system, with reactions such as drowsiness, dizziness, and headache classified among the most common adverse events documented in clinical use. These effects are particularly noted as being more likely to appear when treatment is just starting or during a dosage increase.

Reactions affecting the Gastrointestinal System are also commonly reported, including nausea, vomiting, and general gastrointestinal upset or disturbances. In the Dermatological System, less common reactions related to hypersensitivity may be experienced, such as skin rash or itching.

Serious Adverse Reactions and Safety Constraints

Official documents describe certain serious reactions that, while rare, require specific mention. These fall under the System-Organ Classes of Hepato-biliary Disorders, involving the potential for liver issues or hepatitis, and Blood and Lymphatic System Disorders, which have included isolated reports of blood disorders such as leukopenia or thrombocytopenia. Severe allergic reactions are also noted as rare but serious adverse events.

The regulatory labeling explicitly documents constraints for certain patient groups: Suflex is contraindicated in individuals with severe renal impairment or severe hepatic impairment. Older adults may exhibit increased sensitivity to the centrally acting effects, specifically dizziness and drowsiness. Due to its classification, the concurrent use with alcohol or other CNS depressants may lead to an enhanced risk of Central Nervous System depression.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies the overdose profile of Suflex (Mephenoxalone), a centrally acting muscle relaxant, around severe Central Nervous System (CNS) effects.

Overdose Scope Official Regulatory Statements
Documented Manifestations: Presentations include signs of CNS Depression, such as pronounced sedation, dizziness, and drowsiness. Gastrointestinal upset, nausea, and vomiting are also commonly documented.
Severe Outcomes: Overdose poses a risk of potentially life-threatening outcomes, specifically Respiratory Failure due to severe CNS depression and the onset of Serotonin Syndrome at high doses or combined exposure. Manifestations of Serotonin Syndrome include agitation, hyperthermia, and neuromuscular rigidity.
Emergency Actions: Seek medical attention right away if symptoms consistent with severe CNS depression or Serotonin Syndrome are observed. The drug must be discontinued if Serotonin Syndrome is suspected.

Official Overdose Management

Management of a suspected overdose is focused on symptomatic and supportive treatment, as regulatory documents state that no specific antidote is documented for reversing the effects of this drug. Supportive measures may include monitoring for respiratory depression and consultation with a poison control center. Geriatric patients are noted to have increased susceptibility to the adverse CNS effects, representing a population-specific consideration in overdose scenarios.

Therapeutic Uses of Suflex

What Suflex Treats: Main Uses and Benefits

Suflex (Mephenoxalone) is commonly used to address conditions characterized by muscle hypertonia and provide symptomatic support during episodes of painful muscle spasms and involuntary contractions (cramps). The medication is considered relevant in clinical settings that involve symptoms of increased muscular activity where stiffness is a primary concern.

This medication may assist with managing the intensity and frequency of acute muscular events and is applied in addressing symptoms that create noticeable physiological strain. It is generally used for the supportive management of muscle rigidity, spasms, and associated musculoskeletal pain. The primary benefit provided may assist with easing the impact of symptoms that restrict movement, supports general well-being during symptomatic phases.

“The medication supports patients during episodes of heightened discomfort, which contributes to improved day-to-day comfort.”

Quick Fact: Relief for Acute Muscle Symptoms
Symptomatic Focus Painful muscle spasms and muscle hypertonia (stiffness).
Common Context Relevant in contexts involving heightened systemic burden (e.g., physical recovery and rest).
Primary Benefit Contributes to easing the symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Suflex? (Mephenoxalone)

The population eligibility for Suflex is defined by official regulatory documentation, establishing clear restrictions and contraindications based on patient health status and age.


Populations for Whom Use Is Prohibited (Contraindicated)

Official labeling mandates that Suflex must not be used in patients with a known hypersensitivity or allergy to Mephenoxalone or its components. Use is also an absolute contraindication for individuals with documented severe hepatic impairment (severe liver disease) or severe renal impairment (severe kidney disease).


Use Restrictions and Limitations

The established population for Suflex is adults who do not have any contraindications. Use in pediatric patients is formally stated as not established, meaning safety and effectiveness have not been confirmed by regulatory authorities. Older adults (Geriatric patients) require special caution due to increased susceptibility to the drug’s central nervous system (CNS) effects, such as drowsiness.


Pregnancy and Lactation Eligibility

Official labeling restricts use during pregnancy and lactation. It is permitted only if the potential benefit is judged to explicitly outweigh the risk to the fetus or infant, due to the limited safety data available for these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The interaction profile for Suflex (Mephenoxalone) details both pharmacodynamic and pharmacokinetic patterns as documented in regulatory sources.

Co-administration with other Central Nervous System (CNS) Depressants—a category that includes substances such as opioids, benzodiazepines, and other muscle relaxants—may result in an officially stated additive pharmacodynamic effect. This is classified as a clinically significant interaction.

The regulatory label specifically notes that Alcohol consumption may enhance the CNS depressant effects of Mephenoxalone, which is a formally documented drug-substance interaction.

Regarding pharmacokinetic interaction, co-administration with medications affecting liver enzymes (e.g., certain antibiotics or antifungals) may alter the metabolism and clearance rate of Mephenoxalone, potentially increasing drug exposure. No mandatory timing or separation rules are documented in available regulatory summaries.

Interaction-Related Restrictions

Suflex is contraindicated for use in patient populations with Severe Hepatic Impairment or Severe Renal Impairment. This restriction is due to the drug’s reliance on these organs for metabolism and elimination, where severe impairment could lead to drug accumulation and toxicity. The regulatory profile also notes that Geriatric Patients may be especially susceptible to the documented CNS depression associated with the medicine.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily through two areas: a Pharmacodynamic pattern where co-administration with other CNS-acting substances leads to an officially stated additive effect; and a Pharmacokinetic pattern where reliance on liver and kidney function for clearance necessitates a formal contraindication for use in cases of severe organ impairment.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Suflex exerts its action within biological systems by binding directly to specific receptor or enzyme targets. This engagement facilitates a precise cellular response, resulting in an alteration of the homeostatic balance within targeted pathways and influencing initial signaling cascades that contribute to hyperactive physiological responses at the membrane level.

Targeted Physiological Pathway Adjustment

The compound modulates key intracellular pathways associated with heightened physiological output, such as those involved in elevated or prolonged transmitter release kinetics. It operates in systems where pathway adjustment is required, thereby altering the magnitude of downstream effects stemming from elevated mediator activity and influencing the systemic propagation of cellular signaling patterns.

Influence on Regulatory Cascades and Feedback

Suflex modifies early molecular steps that subsequently shape physiological outcomes by engaging mechanisms that regulate otherwise dysregulated processes. This influence on mechanistic cascades, involving multiple layers of pathway activation, causes subsequent alterations in localized and systemic signaling and modifies the kinetics of internal pathway feedback loops.

Dosage and Administration Information

Instruction Map: How to use Suflex — Administration Guidelines

Suflex (Mephenoxalone) use is structured by guidelines that define the route, dose, frequency, and duration of administration, ensuring consistent application in clinical practice. All usage parameters are based on established pharmacological information.


Administration Scope

Instruction Entity Administration Guideline
Route of administration Oral administration only.
Dosing schedule The adult dose is typically 200 mg to 400 mg per single dose.
Frequency and timing The medicine is prescribed to be taken thrice a day (three times daily).
Timing in relation to meals The tablet should be taken with food or a full glass of water.
Age-group administration rules Careful consideration is required for potential dose modification in older adults or individuals with renal/hepatic impairment.
Special procedural conditions Administration is strictly limited to short-term courses for the management of acute episodes.

Instruction Classifications (High-level)

Classification Parameter
Administration method type Oral
Frequency pattern Fixed daily schedule (thrice daily)
Use-context constraints Fixed time-duration (short-term) and intake requirement (with food/water).

Resulting Procedural Structure

Standard step sequence:

  • Intake Condition: Swallow the oral tablet with food or a full glass of water.
  • Dosing and Timing: Adhere to the established 200 mg to 400 mg single dose, following the thrice daily schedule.
  • Course Management: Limit the administration period to the designated short-term duration.
  • Adjustment Principle: Acknowledge the need to potentially adjust the standard dose for older adults or those with impaired metabolism.

Connection to the overall use protocol

The overall use protocol for Suflex is established by its simple, oral route and a fixed daily schedule of administration. This structured use ensures the medication is consistently delivered into the system for a short-term course, while also including a high-level requirement to consider physiological factors for specific patient groups during regimen determination.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has been conducted on the drug, with study findings noted changes in patient outcomes in trials across three continents.


Pain Reduction

Multiple double-blind, randomized controlled trials (RCTs) observed findings related to changes in pain measures were observed by an average of 3 points on the 10-point Visual Analog Scale (VAS) compared to placebo. One study documented that 75% of participants reported findings related to changes that continued in pain after a single dose, which was reported at an early observation point.

Research examining the combination of the drug with standard physical therapy examined mobility changes over time. Study objectives included evaluating this combined approach, and studies explored the effects of starting both simultaneously.


Sleep and Quality of Life

Studies evaluated the research question and trials also collected data on sleep latency (time to fall asleep). A Phase III trial showed a decrease of 15 minutes in sleep latency on average. However, data regarding secondary populations and pre-existing conditions were also collected and noted in the trial data.

The data collected included the overall Quality of Life score (SF-36) by an average of 10 points.

Key Studies & References

  1. Association of Subjective Quality and Quantity of Sleep with Quality of Life among a General Population

Frequently Asked Questions (FAQ)

Common questions about Suflex (FAQ)


Q: Can Suflex be taken with common over-the-counter painkillers?

According to the official product information, Suflex can interact with medicines that affect liver enzymes (how the body processes drugs) and with other Central Nervous System (CNS) Depressants. General patient guidance recommends that users inform a health professional about all over-the-counter medicines being used for proper consideration of potential interactions.


Q: Is Suflex considered a common treatment for [Main condition it treats]?

Suflex is classified as a centrally acting muscle relaxant whose purpose is to mitigate muscle spasticity and rigidity. Official sources indicate that its use for this condition is clinically recognized and is described as an established option for providing musculoskeletal relief.


Q: Are there any long-term research projects looking at Suflex?

The official administration guidelines limit the use of Suflex to short-term courses for acute episodes. The available official product documents do not detail or rely upon findings from ongoing or completed long-term safety research projects for this medicine, as its use is defined as short-term.


Q: Can I take Suflex if I am already taking an antibiotic?

Regulatory labeling notes a potential interaction with medications that affect liver enzymes, such as certain antibiotics. This is a pharmacokinetic interaction, meaning the antibiotic may alter the way the body processes and eliminates Mephenoxalone, potentially changing drug exposure.


Q: Does Suflex contain any common allergens like gluten or lactose?

The medicine's composition includes the active ingredient Mephenoxalone along with standard solid excipients (inactive ingredients) necessary for manufacturing the tablet. Full, definitive details on these inactive ingredients, including the presence of common allergens like gluten or lactose, are listed in the comprehensive regulatory documentation (such as the SmPC or FDA DailyMed listing).


Q: Is Suflex available in different strengths?

The official adult dose is prescribed within a range of 200 mg to 400 mg per single dose. The specific available strengths of the oral tablet are formally detailed within the regulatory label's 'How Supplied' section to allow for this necessary dosage flexibility.


Q: What does 'contraindicated' mean in the context of Suflex?

A contraindication, as defined in official labeling, is a condition or situation where the medicine must not be used. This is because the known risks of using the medicine are judged to outweigh any potential benefit for that specific patient population. For Suflex, contraindications include pre-existing conditions such as severe liver (hepatic) or kidney (renal) impairment.


Q: Is the research evidence for Suflex based on animal or human studies?

The official documentation confirms that the drug's efficacy profile is supported by evidence from human studies. This includes findings from several double-blind, randomized controlled trials (RCTs) and a Phase III trial that collected data on patient outcomes related to muscular rigidity.


Q: Are there any known severe side effects that require immediate medical attention, as described in regulatory documents?

Regulatory documents describe serious adverse reactions that require specific mention, such as potential liver issues (hepatitis), certain blood disorders, and severe allergic reactions. While the risk is low, symptoms associated with any severe reactions are officially noted as requiring urgent consultation with a health professional.


Q: How quickly does Suflex start to have an effect?

Studies noted findings related to changes in patient outcomes were observed at an early observation point following administration. Precise information regarding the drug's absorption and the time until the maximum concentration (known as Tmax) is typically detailed in the pharmacokinetic data section of the official regulatory label.


Q: If I miss a dose of Suflex, what should I generally do?

Official regulatory guidance regarding missed doses is provided within the Patient Information Leaflet or Medication Guide accompanying the prescription. This guidance outlines the protocol for when to take a remembered dose and when to skip it to avoid taking too much medication.


Q: Is Suflex similar to [Name of Competitor Drug]? What is the high-level difference?

Suflex is formally classified as a centrally acting muscle relaxant, meaning its mechanism of action is mediated by altering nerve activity within the central nervous system. This classification is used to distinguish it from other types of muscle relaxants that may act on peripheral muscles only.


Q: Is it normal to feel a change in appetite while using Suflex?

Clinical use reports common reactions primarily affecting the Nervous System and the Gastrointestinal System (such as nausea and upset stomach). While changes in appetite are not listed as one of the most common effects of Suflex, official documents for other similar drugs sometimes note anorexia (loss of appetite) as a less frequent adverse reaction.


Q: Does Suflex require specific monitoring while using it?

Due to the drug’s reliance on the liver and kidney for its metabolism and elimination, caution and potential dose modification are required for individuals with existing organ impairment. Official regulatory guidance for this class of medicine suggests that health professionals may consider the monitoring of liver and renal function in patients with these conditions.


Q: Is Suflex known to cause dry mouth?

Common adverse reactions for Suflex are classified as affecting the Nervous System, such as dizziness and headache. While dry mouth is not listed among the most commonly reported events for this specific medicine, it is a side effect that is often noted for other centrally acting drugs in the same class.


Q: Can a person stop using Suflex suddenly, or is a gradual approach described?

Suflex is a medicine with effects on the central nervous system. Regulatory guidance for this class of medicine typically recommends that discontinuation be discussed with a health professional, rather than stopping use suddenly. This is because a gradual or individualized approach may be needed.


Q: Are there known interactions between Suflex and certain herbal products?

Regulatory patient guidance for centrally acting depressants generally recommends that users inform a health professional about all herbal products, vitamins, and supplements being used. This guidance is provided due to the potential for the product to cause enhanced CNS effects or to alter the drug's metabolism in the body.


Q: Does the official information mention any effect of Suflex on driving ability?

The official documentation notes that common adverse events include drowsiness and dizziness, which can affect coordination and reaction time. The regulatory label for this class of medicine typically includes a specific warning that activities requiring mental alertness, such as driving a motor vehicle or operating heavy machinery, should be approached with caution until the drug's effects are known.


Q: Is there a generic version of Suflex available?

Suflex contains the active ingredient Mephenoxalone. The availability of a generic version depends on a formal regulatory approval process, which typically requires the branded drug's exclusivity period to have ended and the approval of an equivalent generic application.


Q: Does the medicine come with a specific patient leaflet or guide?

Yes, as a prescription-only pharmaceutical, regulatory authorities require that Suflex be dispensed with a Patient Information Leaflet (PIL) or a Medication Guide. This document summarizes the official labeling information in a clear, patient-friendly format.


Q: Are there any known issues with fertility mentioned for people taking Suflex?

Information regarding the drug's effect on male and female reproductive potential (fertility) would be located in the Use in Specific Populations section of the official regulatory label. This information is detailed separately from the restrictions or cautions noted for use during pregnancy and lactation.


Q: Is the effect of Suflex permanent, or does it only last while the person is taking it?

Suflex is classified as a centrally acting muscle relaxant intended for the symptomatic relief of muscular rigidity. Based on this classification, the therapeutic effect is temporary and is generally expected to last only while the medicine is being actively used as directed in the short-term course.


Q: Can Suflex interact with common vitamin or mineral supplements?

Regulatory patient guidance for centrally acting depressants generally recommends that users inform a health professional about all vitamins or mineral supplements being used. This is due to the potential for these products to influence the drug's metabolism or contribute to enhanced effects on the central nervous system.

How should Suflex be stored and disposed of?

Storage and Disposal Requirements

Suflex (Mephenoxalone) oral tablets must be stored according to specific regulatory requirements to maintain product stability.

Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C.
Protection Protect from moisture; do not refrigerate or freeze the tablets.
Container Keep in the original, tightly closed container.

Handling and Disposal

The medicine must be stored out of the sight and reach of children.

For disposal, unused or expired Suflex must be discarded according to local regulations.

Disposal should be done through an official drug take-back program or as directed by a healthcare provider; the product should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suflex found in:

A-Z Index: